TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3071603

Group type: EXPERIMENTAL
Intervention: Treatment group (Group A: 44 patients) with 10 mg/t.i.d. of p.o. ritodrine, mean hospital stay 15 +/- 5 days
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (Group B: 54 patients), no ritodrine, average hospital stay 7 +/- 3 days
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Treatment group (Group A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 98
Study: 30300148

Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (<10 mg/day, infused over 6 h per treatment)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low-dose alteplase
Number of subjects: 9
Study: 28282844

Group type: EXPERIMENTAL
Intervention: Active tDCS (anodal, 2 mA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 18
Study: 26177871

Group type: EXPERIMENTAL
Intervention: With balloon previous transurethral resection of the prostate laparoscopic radical prostatectomy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: No balloon previous transurethral resection of the prostate laparoscopic radical prostatectomy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control A (surgery-naïve patients)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control B (surgery-naïve patients)
Number of subjects: 25
Study: 22850802

Group type: EXPERIMENTAL
Intervention: Moderate intense treadmill walking (walking group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Specific low back exercise (exercise group)
Number of subjects: 52
Study: 21381465

Group type: EXPERIMENTAL
Intervention: Personal coaching for teachers to improve implementation of the All Stars curriculum
Number of subjects: 48
Study: 17938958

Group type: COMPARATOR
Intervention: Letrozole (MA.17 trial)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Anastrozole (Austrian Breast and Colorectal Cancer Study Group 6a)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Exemestane (National Surgical Adjuvant Breast and Bowel Project B-33 trial)
Number of subjects: 3
Study: 15665207

Group type: EXPERIMENTAL
Intervention: Decline group (single leg squats on a 25 degrees decline board)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Step group (single leg squats on a 10 cm step)
Number of subjects: 17
Study: 12791655

Group type: EXPERIMENTAL
Intervention: Standard-dose chemotherapy
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: High-dose therapy
Number of subjects: 222
Study: 14677621

Group type: EXPERIMENTAL
Intervention: GTD 60 microg/EE 15 microg
Number of subjects: 1074

Group type: COMPARATOR
Intervention: DSG 150 microg/EE 20 microg
Number of subjects: 1074
Study: 8934042

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (estrogen)
Number of subjects: 0
Study: 1880234

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg/d)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg/d)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6974948

Group type: EXPERIMENTAL
Intervention: Droperidol (D series, 30 cases)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (L series, 30 cases)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both interventions (Droperidol and Chlorpromazine)
Number of subjects: 60
Study: 31798019

Group type: EXPERIMENTAL
Intervention: TCDD group (single dose of TCDD applied 21 days before 1% carrageenan solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: C group (1% carrageenan solution without TCDD)
Number of subjects: 0
Study: 28445854

Group type: EXPERIMENTAL
Intervention: Therapist-supervised balance training for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home-based balance training for 8 weeks
Number of subjects: 40
Study: 25971836

Group type: EXPERIMENTAL
Intervention: Exercise Assisted Reduction then Stop (EARS) smoking intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Community outreach approaches
Number of subjects: 93
Study: 23535197

Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 123
Study: 21262061

Group type: EXPERIMENTAL
Intervention: Validation group using GRPACA with triaxial accelerometer
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cross-validation group using GRPACA-based linear regression models
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Specific linear regression for sedentary activities
Number of subjects: 66
Study: 19824078

Group type: EXPERIMENTAL
Intervention: Betaine (20 g daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 16978993

Group type: EXPERIMENTAL
Intervention: Facilitated angioplasty
Number of subjects: 17

Group type: COMPARATOR
Intervention: Facilitated angioplasty with full- or half-dose thrombolysis
Number of subjects: 17

Group type: COMPARATOR
Intervention: Primary angioplasty
Number of subjects: 17
Study: 15309702

Group type: EXPERIMENTAL
Intervention: VAS score (Visual Analog Scale)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duke Activity Status Index (DASI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New York Heart Association functional class
Number of subjects: 0
Study: 11713356

Group type: EXPERIMENTAL
Intervention: Inhaled IL-5 (15 microg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous IL-5 (2 microg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9009126

Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8232870

Group type: EXPERIMENTAL
Intervention: Gadodiamide injection (Omniscan)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Gadolinium-DOTA
Number of subjects: 58
Study: 3318971

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (100-200 mg per day orally in two divided doses)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study: 28399015

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional Western Diet (WD)
Number of subjects: 25
Study: 28647284

Group type: EXPERIMENTAL
Intervention: 1:1 work-to-rest ratio HIIT group (SIT; n=16)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 2:1 work-to-rest ratio HIIT group (LIT; n=19)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (CON; n=9)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HIIT (both SIT and LIT)
Number of subjects: 44
Study: 26985607

Group type: EXPERIMENTAL
Intervention: Community health worker counseling
Number of subjects: 209

Group type: COMPARATOR
Intervention: Registered nurse counseling
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 209
Study: 24994597

Group type: EXPERIMENTAL
Intervention: Melacine vaccine for 2 years
Number of subjects: 689

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Melacine vaccine in HLA-A2 and/or HLA-Cw3 serotype patients (n = 178)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Observation in HLA-A2 and/or HLA-Cw3 serotype patients
Number of subjects: 689
Study: 22906744

Group type: EXPERIMENTAL
Intervention: Comprehensive training program including awareness, instruction, and practice with feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practice with Feedback (component of the comprehensive training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained control condition
Number of subjects: 0
Study: 20385511

Group type: EXPERIMENTAL
Intervention: Long protocol plus NAC (group B)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Long protocol (group A)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study: 17251232

Group type: EXPERIMENTAL
Intervention: Nebulised budesonide (NB) 1,500 microg q.i.d. plus standard bronchodilator treatment (SBDT)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids (SC) 40 mg prednisolone plus standard bronchodilator treatment (SBDT)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Standard bronchodilator treatment (SBDT) only
Number of subjects: 159
Study: 15485130

Group type: EXPERIMENTAL
Intervention: NRT-based MAP (n = 5)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Behavioral-based MAP (n = 5)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NRT-based MAP
Number of subjects: 10

Group type: COMPARATOR
Intervention: Behavioral-based MAP
Number of subjects: 10
Study: 11164322

Group type: EXPERIMENTAL
Intervention: Frequently Asked Questions checklist with written instructions and brochure from the Dutch Heart Foundation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (brochure only)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Frequently Asked Questions checklist
Number of subjects: 103
Study: 10216540

Group type: EXPERIMENTAL
Intervention: PGE1 infusion started at 0.05 microgram/kg/min, decreased to 0.005-0.01 microgram/kg/min for maintenance.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PGE1 infusion for Group I (pulmonary blood flow increase) and Group III (mixing improvement).
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PGE1 infusion for Group II (systemic blood flow increase).
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PGE1 infusion for Group IV (left ventricular volume improvement).
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PGE1 usage duration.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PGE1 related deaths.
Number of subjects: 65
Study: 7638388

Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament retention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Postero-stabilised prosthesis
Number of subjects: 48
Study: 3070014

Group type: EXPERIMENTAL
Intervention: Aerobic training condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation training condition
Number of subjects: 0
Study: 28940909

Group type: EXPERIMENTAL
Intervention: High ectopic burden (>10 VPCs/hour)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Low ectopic burden (≤10 VPCs/hour)
Number of subjects: 698
Study: 27466244

Group type: EXPERIMENTAL
Intervention: Falls prevention education
Number of subjects: 757
Study: 24415665

Group type: EXPERIMENTAL
Intervention: G‐CSF (5 µg/Kg body weight b.i.d.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22944274

Group type: EXPERIMENTAL
Intervention: High-dose tirofiban
Number of subjects: 104

Group type: COMPARATOR
Intervention: Normal-dose tirofiban
Number of subjects: 104
Study: 18838406

Group type: EXPERIMENTAL
Intervention: Eccentric exercises with night splint
Number of subjects: 58

Group type: COMPARATOR
Intervention: Eccentric exercises without night splint
Number of subjects: 58
Study: 18245919

Group type: EXPERIMENTAL
Intervention: Ibuprofen administered prior to surgery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no ibuprofen administered)
Number of subjects: 10
Study: 15728080

Group type: COMPARATOR
Intervention: 0.75% ropivacaine followed by 0.2% ropivacaine (group control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine and 1 microg/kg clonidine followed by 0.2% ropivacaine (group cloni-bolus)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine and 1 microg/kg clonidine followed by 0.2% ropivacaine with 1 microg/mL clonidine (group cloni-infusion)
Number of subjects: 60
Study: 15228784

Group type: EXPERIMENTAL
Intervention: Women's Initiative for Sexual Health intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 0
Study: 11679974

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 121
Study: 9234663

Group type: EXPERIMENTAL
Intervention: Stepwise dobutamine-infusion protocol (10-40 microg/kg/min, 3-min intervals)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Continuous dobutamine-infusion protocol (10 microg/kg/min for 12 min)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Stepwise dobutamine-infusion protocol
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Continuous dobutamine-infusion protocol
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 43
Study: 7900237

Group type: EXPERIMENTAL
Intervention: Immunotherapy with low-dose IL-2 (3 million IU/day subcutaneously for 6 days/week for 4 weeks) plus melatonin (40 mg/day orally, starting 7 days before IL-2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy with cisplatin (20 mg/m2) and etoposide (100 mg/m2/day intravenously for 3 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Immunotherapy with low-dose IL-2 plus MLT
Number of subjects: 60
Study: 3068951

Group type: EXPERIMENTAL
Intervention: Cyclopentolate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homatropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclopentolate vs Homatropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Homatropine vs Atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine vs Cyclopentolate
Number of subjects: 0
Study: 31621254

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture combined with dydrogesterone (10 mg orally twice a day until 12 weeks of pregnancy)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dydrogesterone (10 mg orally twice a day until 12 weeks of pregnancy)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture combined with dydrogesterone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dydrogesterone
Number of subjects: 80
Study: 28179049

Group type: EXPERIMENTAL
Intervention: Tailored behavior change techniques implemented in educational training sessions and feedback discussions in the intervention arm.
Number of subjects: 29

Group type: COMPARATOR
Intervention: ASH training sessions provided in the control arm.
Number of subjects: 29
Study: 26163200

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: UR‐1505 0.5%
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: UR‐1505 1%
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: UR‐1505 2%
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1%
Number of subjects: 28
Study: 22964169

Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg twice daily plus subcutaneous IFN, 9 million units (MU) three times a week (Arm A)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg twice daily plus subcutaneous IFN, 3 MU five times a week (Arm B)
Number of subjects: 101
Study: 21221804

Group type: EXPERIMENTAL
Intervention: Daily CIFN (15 mcg/day SQ) and RBV (1‐1.2 g/d PO) for 52 weeks (group A, n = 33)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Daily CIFN (15 mcg/day SQ) and RBV (1‐1.2 g/d PO) for 52-72 weeks (group B, n = 31)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overall treatment (n=64)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Patients with RVR at 4 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Patients with early virologic response from 8‐12 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Patients with late virologic response from 16‐24 weeks
Number of subjects: 64
Study: 18828055

Group type: EXPERIMENTAL
Intervention: Single dose ceftriaxone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Combination of ampiclox, gentamicin, and metronidazole
Number of subjects: 200
Study: 16497600

Group type: EXPERIMENTAL
Intervention: Intervention group (smokers) - 22 participants
Number of subjects: 121

Group type: COMPARATOR
Intervention: Comparison group (smokers) - 31 participants
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intervention group (never-smokers) - 24 participants
Number of subjects: 121

Group type: COMPARATOR
Intervention: Comparison group (never-smokers) - 32 participants
Number of subjects: 121
Study: 12971972

Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b 5 MU daily for 4 weeks, 5 MU tiw for 20 weeks, followed by 3 MU tiw for additional 24 weeks combined with ribavirin 1000-1200 mg/d plus amantadine sulphate 100 mg bid for 48 weeks
Number of subjects: 225

Group type: COMPARATOR
Intervention: IFN-alpha/ribavirin alone
Number of subjects: 225
Study: 11115443

Group type: EXPERIMENTAL
Intervention: NPPV plus standard care
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 52
Study: 9083317

Group type: EXPERIMENTAL
Intervention: Sweeping membranes
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (Bishop score only)
Number of subjects: 150
Study: 8257235

Group type: EXPERIMENTAL
Intervention: 5,6 benzo-alpha-pyrone (56 BaP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of 56 BaP and DEC
Number of subjects: 40
Study: 3898285

Group type: EXPERIMENTAL
Intervention: Thymopentin (1 mg/kg daily i.m. for 2 weeks, then 1 mg/kg 3 times weekly for 10 weeks)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31452319

Group type: EXPERIMENTAL
Intervention: Eculizumab (Ecu)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 30502307

Group type: COMPARATOR
Intervention: Phase 1 (usual care)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Phase 2 (oral anticoagulation prescription tool and patient education)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Phase 3 (oral anticoagulation prescription tool, patient materials, educational session, and follow-up clinic)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Phase 3 vs Phase 2
Number of subjects: 631

Group type: COMPARATOR
Intervention: Phase 1
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Phase 2
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Phase 3
Number of subjects: 631
Study: 26576937

Group type: EXPERIMENTAL
Intervention: Resistance training intervention for knee extension over 12 weeks
Number of subjects: 11
Study: 26380361

Group type: EXPERIMENTAL
Intervention: Strength training at the workplace for 20 minutes, three times per week
Number of subjects: 18
Study: 23946704

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil once daily for 4 weeks
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo once daily for 4 weeks
Number of subjects: 114
Study: 21251795

Group type: EXPERIMENTAL
Intervention: Immediate-release opioid administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched-placebo administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immediate-release opioid administration in high PCS scorers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched-placebo administration in high PCS scorers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immediate-release opioid administration in low PCS scorers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched-placebo administration in low PCS scorers
Number of subjects: 20
Study: 19091796

Group type: EXPERIMENTAL
Intervention: Vitamin A (240 mg in 4 doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17205963

Group type: EXPERIMENTAL
Intervention: 5-leucine repeat CNDP1 genotype (5-5) in diabetic patients lacking nephropathy
Number of subjects: 858

Group type: COMPARATOR
Intervention: 5-leucine repeat CNDP1 genotype (5-5) in healthy controls
Number of subjects: 858

Group type: COMPARATOR
Intervention: 5-leucine repeat CNDP1 genotype (5-5) in healthy controls vs DM cases without nephropathy
Number of subjects: 858
Study: 15093907

Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (50.4 Gy in 28 fractions)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: High-dose radiotherapy (64.8 Gy in 36 fractions)
Number of subjects: 203
Study: 11514072

Group type: EXPERIMENTAL
Intervention: First-degree relatives of patients with schizophrenia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with schizophrenia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 9627294

Group type: EXPERIMENTAL
Intervention: Sepracoat (HAL-C) solution
Number of subjects: 277

Group type: COMPARATOR
Intervention: Phosphate-buffered saline (placebo)
Number of subjects: 277
Study: 7887100

Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen
Number of subjects: 47

Group type: COMPARATOR
Intervention: Air-oxygen (control)
Number of subjects: 47
Study: 3269505

Group type: EXPERIMENTAL
Intervention: Hydrogel lenses with varying water content
Number of subjects: 6
Study: 31985862

Group type: EXPERIMENTAL
Intervention: Family-centred empowerment program
Number of subjects: 70
Study: 30699073

Group type: EXPERIMENTAL
Intervention: Experimental pain group (n=17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 34
Study: 28130659

Group type: EXPERIMENTAL
Intervention: Pitavastatin 1-4 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitavastatin with lifestyle modification advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 0
Study: 26440236

Group type: EXPERIMENTAL
Intervention: Desflurane-fentanyl based technique
Number of subjects: 76

Group type: COMPARATOR
Intervention: Total IV anesthesia (TIVA)
Number of subjects: 76
Study: 23541248

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site surgery (LESS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Multi-port surgery
Number of subjects: 20
Study: 21289249

Group type: EXPERIMENTAL
Intervention: D(2) daily dosing (1,600 IU)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: D(3) monthly dosing (50,000 IU)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: D(2) dosing
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: D(3) dosing
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: D(2) or D(3) dosing (1,600 IU daily or 50,000 IU monthly)
Number of subjects: 64
Study: 19053979

Group type: EXPERIMENTAL
Intervention: XR-NTX 380 mg
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: XR-NTX 190 mg
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 18043303

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual activity
Number of subjects: 55